Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
6 affiliations
- 1St. John’s Episcopal Hospital
- 2Washington University School of Medicine
- 3Ponce Health Sciences University
- 4Washington University in St. Louis
- 5Aurora Health Care
- 6University of Texas Health San Antonio
Abstract
Background Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death. Methods This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Results GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P <0.001). Semaglutide or tirzepatide use was also associated with lower risks of MI, HF, and death (all P <0.001). Findings were directionally consistent after accounting for sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Conclusions Adults with treated SMI, type 2 diabetes, and obesity using GLP‐1RAs, particularly semaglutide or tirzepatide, had significantly reduced 1‐ and 3‐year risks of incident MI, HF, and all‐cause death versus nonusers. These pooled associations should be interpreted in the context of SMI's clinical heterogeneity and the limitations of administrative case ascertainment.
Related
- Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists
- Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review
- Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention
- Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness
- Use of SGLT2 Inhibitors, GLP‐1 Receptor Agonists, and DPP‐4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations
BibTeX
@article{governor2026glucagonlike,
title = {{Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity}},
author = {Samuel B. Governor and David M. Dávila‐García and Eliut Rivera‐Segarra and Lindsey M. Filiatreau and Nelmit Tollinchi‐Natali and Ekow Essien and Osamah Altaee and Prince Otchere and Leopoldo J. Cabassa and Victor G. Dávila‐Román},
journal = {Journal of the American Heart Association},
year = {2026},
month = oct,
doi = {10.1161/jaha.126.051982},
url = {https://www.ahajournals.org/doi/10.1161/JAHA.126.051982},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
AU - Samuel B. Governor
AU - David M. Dávila‐García
AU - Eliut Rivera‐Segarra
AU - Lindsey M. Filiatreau
AU - Nelmit Tollinchi‐Natali
AU - Ekow Essien
AU - Osamah Altaee
AU - Prince Otchere
AU - Leopoldo J. Cabassa
AU - Victor G. Dávila‐Román
PY - 2026
DA - 2026/10/20
JO - Journal of the American Heart Association
DO - 10.1161/jaha.126.051982
UR - https://www.ahajournals.org/doi/10.1161/JAHA.126.051982
AB - Background Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death. Methods This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Results GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P <0.001). Semaglutide or tirzepatide use was also associated with lower risks of MI, HF, and death (all P <0.001). Findings were directionally consistent after accounting for sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Conclusions Adults with treated SMI, type 2 diabetes, and obesity using GLP‐1RAs, particularly semaglutide or tirzepatide, had significantly reduced 1‐ and 3‐year risks of incident MI, HF, and all‐cause death versus nonusers. These pooled associations should be interpreted in the context of SMI's clinical heterogeneity and the limitations of administrative case ascertainment.
SN - 2047-9980
ER -